These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 11342363

  • 1. Cytarabine added to interferon improves the cost-effectiveness of initial therapy for patients with early chronic phase chronic myelogenous leukemia.
    Beck JR, Guilhot J, Giles FJ, Aoki N, Wirt DP, Guilhot F.
    Leuk Lymphoma; 2001 Mar; 41(1-2):117-24. PubMed ID: 11342363
    [Abstract] [Full Text] [Related]

  • 2. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.
    Kantarjian HM, O'Brien S, Smith TL, Rios MB, Cortes J, Beran M, Koller C, Giles FJ, Andreeff M, Kornblau S, Giralt S, Keating MJ, Talpaz M.
    J Clin Oncol; 1999 Jan; 17(1):284-92. PubMed ID: 10458244
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
    Reed SD, Anstrom KJ, Ludmer JA, Glendenning GA, Schulman KA.
    Cancer; 2004 Dec 01; 101(11):2574-83. PubMed ID: 15493042
    [Abstract] [Full Text] [Related]

  • 4. Results of therapy with interferon alpha and cyclic combination chemotherapy in patients with philadelphia chromosome positive chronic myelogenous leukemia in early chronic phase.
    Giles FJ, Kantarjian H, O'Brien S, Rios MB, Cortes J, Beran M, Koller C, Keating M, Talpaz M.
    Leuk Lymphoma; 2001 Apr 01; 41(3-4):309-19. PubMed ID: 11378543
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of interferon alfa in chronic myelogenous leukemia.
    Liberato NL, Quaglini S, Barosi G.
    J Clin Oncol; 1997 Jul 01; 15(7):2673-82. PubMed ID: 9215840
    [Abstract] [Full Text] [Related]

  • 6. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.
    O'Brien S, Talpaz M, Cortes J, Shan J, Giles FJ, Faderl S, Thomas D, Garcia-Manero G, Mallard S, Beth M, Koller C, Kornblau S, Andreeff M, Murgo A, Keating M, Kantarjian HM.
    Cancer; 2002 Apr 01; 94(7):2024-32. PubMed ID: 11932905
    [Abstract] [Full Text] [Related]

  • 7. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group.
    Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau JL, Maloisel F, Bouabdallah R, Guyotat D, Cheron N, Nicolini F, Abgrall JF, Tanzer J.
    N Engl J Med; 1997 Jul 24; 337(4):223-9. PubMed ID: 9227927
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of interferon-alpha and conventional chemotherapy in chronic myelogenous leukemia.
    Kattan MW, Inoue Y, Giles FJ, Talpaz M, Ozer H, Guilhot F, Zuffa E, Huber SL, Beck JR.
    Ann Intern Med; 1996 Oct 01; 125(7):541-8. PubMed ID: 8815752
    [Abstract] [Full Text] [Related]

  • 9. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine.
    Kantarjian HM, Keating MJ, Estey EH, O'Brien S, Pierce S, Beran M, Koller C, Feldman E, Talpaz M.
    J Clin Oncol; 1992 May 01; 10(5):772-8. PubMed ID: 1569449
    [Abstract] [Full Text] [Related]

  • 10. Long-term follow-up results of alpha-interferon-based regimens in patients with late chronic phase chronic myelogenous leukemia.
    Sacchi S, Kantarjian HM, O'Brien S, Beran M, Koller C, Pierce S, Kornblau S, Estey E, Keating MJ, Talpaz M.
    Leukemia; 1997 Oct 01; 11(10):1610-6. PubMed ID: 9324278
    [Abstract] [Full Text] [Related]

  • 11. High response rate using recombinant interferon-alpha in patients with newly diagnosed chronic myeloid leukemia.
    Mahon FX, Fabères C, Montastruc M, Si-Mour S, Boiron JM, Marit G, Bilhou-Nabera C, Cony-Makhoul P, Pigneux A, Bernard P, Broustet A, Reiffers J.
    Bone Marrow Transplant; 1996 May 01; 17 Suppl 3():S33-7. PubMed ID: 8769698
    [Abstract] [Full Text] [Related]

  • 12. Hematological and cytogenetic response of interferon alpha 2b alone and combined interferon alpha plus cytarabine as a first-line treatment in chronic myeloid leukemia.
    Tóthová E, Fricová M, Kafková A, Stecová N, Guman T, Raffac S, Hlebasková M.
    Neoplasma; 2000 May 01; 47(2):125-8. PubMed ID: 10985480
    [Abstract] [Full Text] [Related]

  • 13. Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea.
    Hehlmann R, Berger U, Pfirrmann M, Hochhaus A, Metzgeroth G, Maywald O, Hasford J, Reiter A, Hossfeld DK, Kolb HJ, Löffler H, Pralle H, Queisser W, Griesshammer M, Nerl C, Kuse R, Tobler A, Eimermacher H, Tichelli A, Aul C, Wilhelm M, Fischer JT, Perker M, Scheid C, Schenk M, Weiss J, Meier CR, Kremers S, Labedzki L, Schmeiser T, Lohrmann HP, Heimpel H, German CML-Study Group.
    Leukemia; 2003 Aug 01; 17(8):1529-37. PubMed ID: 12886239
    [Abstract] [Full Text] [Related]

  • 14. Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583.
    Ozer H, George SL, Schiffer CA, Rao K, Rao PN, Wurster-Hill DH, Arthur DD, Powell B, Gottlieb A, Peterson BA, Rai K, Testa JR, LeBeau M, Tantravahi R, Bloomfield CD.
    Blood; 1993 Nov 15; 82(10):2975-84. PubMed ID: 8219189
    [Abstract] [Full Text] [Related]

  • 15. Management of chronic myeloid leukemia in chronic phase with autologous stem cell transplantation and alpha-2 interferon: cytogenetic and clinical results.
    Alimena G, Meloni G, de Cuia MR, Rondinelli MB, Lo Coco F, Montefusco E, Mancini M, Pinto R, Nanni M, Cedrone M.
    Leuk Lymphoma; 1993 Nov 15; 11 Suppl 1():281-91. PubMed ID: 7902746
    [Abstract] [Full Text] [Related]

  • 16. Results of a phase II trial testing interferon-alpha 2b and cytarabine in children and adolescents with chronic myelogenous leukemia.
    Millot F, Guilhot J, Nelken B, Leblanc T, Leverger G, Bernard F, Gandemer V, Béhard C, Berger C, Cornu G, Duchène S, Guilhot F.
    Pediatr Blood Cancer; 2006 Oct 15; 47(5):555-9. PubMed ID: 16317737
    [Abstract] [Full Text] [Related]

  • 17. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
    O'Brien S, Giles F, Talpaz M, Cortes J, Rios MB, Shan J, Thomas D, Andreeff M, Kornblau S, Faderl S, Garcia-Manero G, White K, Mallard S, Freireich E, Kantarjian HM.
    Cancer; 2003 Sep 01; 98(5):888-93. PubMed ID: 12942553
    [Abstract] [Full Text] [Related]

  • 18. High-dose chemo-radiotherapy followed by autologous Philadelphia chromosome-negative blood progenitor cell transplantation in patients with chronic myelogenous leukemia.
    Carella AM, Chimirri F, Podestà M, Pitto A, Piaggio G, Dejana A, Lerma E, Pollicardo N, Vassallo F, Soracco M, Benvenuto F, Valbonesi M, Carlier P, Vimercati R, Prencipe E, Gatti AM, Ferrara RA, Incagliato M, Florio G, Frassoni F.
    Bone Marrow Transplant; 1996 Feb 01; 17(2):201-5. PubMed ID: 8640167
    [Abstract] [Full Text] [Related]

  • 19. Cost-Effectiveness of interferon alfa-2b added to chemotherapy for high-tumor-burden follicular non-Hodgkin's lymphoma.
    Wirt DP, Giles FJ, Oken MM, Solal-Celigny P, Beck JR.
    Leuk Lymphoma; 2001 Feb 01; 40(5-6):565-79. PubMed ID: 11426529
    [Abstract] [Full Text] [Related]

  • 20. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
    O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ, IRIS Investigators.
    N Engl J Med; 2003 Mar 13; 348(11):994-1004. PubMed ID: 12637609
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.